Can a female-to-male (FTM) transitioning individual on testosterone (hormone replacement therapy) therapy stop or titrate down their testosterone dosage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testosterone Discontinuation and Dose Reduction in Female-to-Male Transition

Yes, testosterone can be stopped or titrated down in transgender men, but doing so will result in physiological changes reverting toward baseline within 3 months, and inadequate dosing negatively impacts bone density and may compromise quality of life. 1, 2

Physiological Effects of Stopping or Reducing Testosterone

  • When testosterone therapy is discontinued, laboratory values and physical characteristics return to baseline within 3 months, including red blood cell indices, liver enzymes, creatinine, and QTc intervals reverting to female reference ranges 1

  • Inadequate testosterone dosing can negatively impact bone density, making appropriate dosing and monitoring essential for skeletal health 2

  • After stopping testosterone, clinical interpretation of lab values should use the reference range for sex assigned at birth once therapy has been stopped for ≥3 months 1

Clinical Considerations for Dose Reduction

  • The standard target testosterone level is 300-1,000 ng/dL (mid-normal male range), and levels below this range may not provide adequate masculinization or bone protection 2, 3

  • Testosterone can be titrated down in increments, but maintaining trough levels below 300 ng/dL risks inadequate hormonal support for bone health and may result in return of menses and loss of masculinizing effects 2

  • Gender-affirming hormone therapy with testosterone is medically necessary for many transgender individuals, with strong evidence showing improvements in quality of life and relief of psychological distress associated with gender dysphoria 2, 4

Monitoring After Dose Reduction or Discontinuation

  • Monitor testosterone levels at 3 months after any dose adjustment or discontinuation to assess hormonal status 2, 5

  • Check bone density if testosterone is discontinued long-term or maintained at subtherapeutic levels, as inadequate androgen exposure increases osteoporosis risk 2

  • Hemoglobin will decrease to female reference range within 3 months of stopping testosterone, eliminating the need for polycythemia monitoring 1, 2

  • After 3 months off testosterone, interpret all lab values (creatinine, red blood cell indices, QTc) using female reference ranges 1

Common Clinical Scenarios

  • Patients considering pregnancy must stop testosterone, as it is contraindicated during pregnancy and fertility may return after discontinuation 6, 7

  • Some individuals may prefer low-dose testosterone to achieve partial masculinization, though long-term safety data for this approach is limited 6

  • Older transgender men may require dose adjustment due to age-related changes in metabolism and cardiovascular risk, though specific guidelines for geriatric dose reduction are lacking 8

Critical Pitfalls to Avoid

  • Do not abruptly stop testosterone without counseling the patient about expected physical changes, including return of menses, voice changes stabilizing but not reversing, and potential psychological distress 2, 4

  • Avoid maintaining subtherapeutic testosterone levels long-term without monitoring bone density, as this creates a hypogonadal state that increases fracture risk 2

  • Do not assume all masculinizing effects will reverse - voice deepening and facial hair growth are largely permanent even after testosterone discontinuation 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hormone Therapy for Female-to-Male Transition

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Progress on the road to better medical care for transgender patients.

Current opinion in endocrinology, diabetes, and obesity, 2013

Research

Hormone Therapy for Transgender Adults.

The Urologic clinics of North America, 2019

Research

Recommendations for the Use of Testosterone in Male Transgender.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2018

Research

Testosterone and other treatments for transgender males and non-binary trans masculine individuals.

Best practice & research. Clinical endocrinology & metabolism, 2024

Research

Hormone therapy for transgender patients.

Translational andrology and urology, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.